145 related articles for article (PubMed ID: 22832397)
1. Economics of medically unexplained symptoms: a systematic review of the literature.
Konnopka A; Schaefert R; Heinrich S; Kaufmann C; Luppa M; Herzog W; König HH
Psychother Psychosom; 2012; 81(5):265-75. PubMed ID: 22832397
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of interventions for medically unexplained symptoms: A systematic review.
Wortman MSH; Lokkerbol J; van der Wouden JC; Visser B; van der Horst HE; Olde Hartman TC
PLoS One; 2018; 13(10):e0205278. PubMed ID: 30321193
[TBL] [Abstract][Full Text] [Related]
3. Association of costs with somatic symptom severity in patients with medically unexplained symptoms.
Konnopka A; Kaufmann C; König HH; Heider D; Wild B; Szecsenyi J; Herzog W; Heinrich S; Schaefert R
J Psychosom Res; 2013 Oct; 75(4):370-5. PubMed ID: 24119945
[TBL] [Abstract][Full Text] [Related]
4. Mindfulness-based cognitive therapy for patients with medically unexplained symptoms: a cost-effectiveness study.
van Ravesteijn H; Grutters J; olde Hartman T; Lucassen P; Bor H; van Weel C; van der Wilt GJ; Speckens A
J Psychosom Res; 2013 Mar; 74(3):197-205. PubMed ID: 23438709
[TBL] [Abstract][Full Text] [Related]
5. Somatization increases medical utilization and costs independent of psychiatric and medical comorbidity.
Barsky AJ; Orav EJ; Bates DW
Arch Gen Psychiatry; 2005 Aug; 62(8):903-10. PubMed ID: 16061768
[TBL] [Abstract][Full Text] [Related]
6. Cost-of-illness studies and cost-effectiveness analyses in anxiety disorders: a systematic review.
Konnopka A; Leichsenring F; Leibing E; König HH
J Affect Disord; 2009 Apr; 114(1-3):14-31. PubMed ID: 18768222
[TBL] [Abstract][Full Text] [Related]
7. Cost-of-illness studies and cost-effectiveness analyses in eating disorders: a systematic review.
Stuhldreher N; Konnopka A; Wild B; Herzog W; Zipfel S; Löwe B; König HH
Int J Eat Disord; 2012 May; 45(4):476-91. PubMed ID: 22294558
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness Analysis of a Stepped, Collaborative and Coordinated Health Care Network for Patients with Somatoform Disorders (Sofu-Net).
Grochtdreis T; Brettschneider C; Shedden-Mora M; Piontek K; König HH; Löwe B
J Ment Health Policy Econ; 2018 Jun; 21(2):59-69. PubMed ID: 29961045
[TBL] [Abstract][Full Text] [Related]
9. Systematic review and quality assessment of economic evaluations and quality-of-life studies related to generalized anxiety disorder.
Bereza BG; Machado M; Einarson TR
Clin Ther; 2009 Jun; 31(6):1279-308. PubMed ID: 19695395
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of a new treatment for somatized mental disorder taught to GPs.
Morriss R; Gask L; Ronalds C; Downes-Grainger E; Thompson H; Leese B; Goldberg D
Fam Pract; 1998 Apr; 15(2):119-25. PubMed ID: 9613478
[TBL] [Abstract][Full Text] [Related]
11. Costs of an intervention for primary care patients with medically unexplained symptoms: a randomized controlled trial.
Luo Z; Goddeeris J; Gardiner JC; Smith RC
Psychiatr Serv; 2007 Aug; 58(8):1079-86. PubMed ID: 17664519
[TBL] [Abstract][Full Text] [Related]
12. Cost-of-illness studies in systemic lupus erythematosus: A systematic review.
Zhu TY; Tam LS; Li EK
Arthritis Care Res (Hoboken); 2011 May; 63(5):751-60. PubMed ID: 21557530
[TBL] [Abstract][Full Text] [Related]
13. Economic Cost of Functional Neurologic Disorders: A Systematic Review.
O'Mahony B; Nielsen G; Baxendale S; Edwards MJ; Yogarajah M
Neurology; 2023 Jul; 101(2):e202-e214. PubMed ID: 37339887
[TBL] [Abstract][Full Text] [Related]
14. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
15. Economic Burden of Anxiety Disorders: A Systematic Review and Meta-Analysis.
Konnopka A; König H
Pharmacoeconomics; 2020 Jan; 38(1):25-37. PubMed ID: 31646432
[TBL] [Abstract][Full Text] [Related]
16. Towards better understanding and management of somatoform disorders.
Janca A; Isaac M; Ventouras J
Int Rev Psychiatry; 2006 Feb; 18(1):5-12. PubMed ID: 16451875
[TBL] [Abstract][Full Text] [Related]
17. Cost measurement of mental disorders in Germany.
Grupp H; Köenig HH; Konnopka A
J Ment Health Policy Econ; 2014 Mar; 17(1):3-8. PubMed ID: 24864116
[TBL] [Abstract][Full Text] [Related]
18. Cost of illness for bipolar disorder: a systematic review of the economic burden.
Kleine-Budde K; Touil E; Moock J; Bramesfeld A; Kawohl W; Rössler W
Bipolar Disord; 2014 Jun; 16(4):337-53. PubMed ID: 24372893
[TBL] [Abstract][Full Text] [Related]
19. A controlled treatment study of somatoform disorders including analysis of healthcare utilization and cost-effectiveness.
Hiller W; Fichter MM; Rief W
J Psychosom Res; 2003 Apr; 54(4):369-80. PubMed ID: 12670616
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
